Impact of Diabetes Mellitus on Angiographic and Clinical Outcomes in the Drug-Eluting Stents Era
Authors:
- Seong-Wook ParkSPSeong-Wook Park
- Cheol Whan LeeCLCheol Whan Lee
- 1 November 2005
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 96 (10) , 1389-1392
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent RestenosisJAMA, 2005
- Impact of Sirolimus-Eluting Stents on Outcome in Diabetic PatientsCirculation, 2004
- A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 2004
- Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients Insights from the RAVEL TrialEuropean Heart Journal, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Paclitaxel Coating Reduces In-Stent Intimal Hyperplasia in Human Coronary ArteriesCirculation, 2003
- Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) TrialCirculation, 2002
- Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting StentsCirculation, 2001